IBRX Immunitybio Inc

MIRAMAR, Fla., Aug. 18, 2025 ( GLOBE NEWSWIRE ) -- HCW Biologics Inc. ( the "Company" or "HCW Biologics" ) ( NASDAQ: HCWB ) , a clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen health span by disrupting the link between inflammation ...

ImmunityBio ( NASDAQ:IBRX ) , a commercial-stage biotechnology company, released its second-quarter results on August 5, 2025. The main headline: revenue ( GAAP ) jumped to $26.4 million, soundly beating analyst GAAP revenue estimates of $23.15 million, as commercial sales of the immunotherapy ...

ImmunityBio (IBRX) delivered earnings and revenue surprises of 0.00% and +0.10%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Los Angeles Times owner Patrick Soon-Shiong announced plans to take the 143-year-old newspaper public within the next year,

CG Oncology stock surges 27% in a month following superior efficacy data from its phase III study of cretostimogene for a bladder cancer indication.

MIRAMAR, Fla., May 15, 2025 ( GLOBE NEWSWIRE ) -- HCW Biologics Inc. ( the "Company" or "HCW Biologics" ) ( NASDAQ: HCWB ) , a clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen health span by disrupting the link between inflammation ...